UBS says Argenx stopped Vyvgart Sjogren trial at interim
UBS analysts said Argenx’s discontinuation of its late-stage Vyvgart study in Sjogren’s disease at interim suggests limited efficacy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.